Amy Burroughs to lead Cleave Therapeutics; Cynthia Collins clinches Editas CEO job amid historic CRISPR move
→ After bagging $12 million to advance its lead drug candidate CB-5339 — a (VCP)/p97 inhibitor — through early clinical development, Cleave Therapeutics is beefing up its executive team. Amy Burroughs will be leading the helm as CEO while Scott Harris joins as COO. Burroughs was an executive-in-residence at 5AM Ventures, which led the recent financing, where she also served as a strategic commercial advisor to portfolio company Crinetics Pharmaceuticals. Given her early experience with the team at Genentech and background in life sciences consulting, Burroughs brings critical perspectives on “understanding market needs, building partnerships and attracting top-notch talent,” said board chairman and former Cleave CEO Laura Shawver.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters